These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22544389)

  • 1. Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies.
    Honarparvar B; Makatini MM; Pawar SA; Petzold K; Soliman ME; Arvidsson PI; Sayed Y; Govender T; Maguire GE; Kruger HG
    ChemMedChem; 2012 Jun; 7(6):1009-19. PubMed ID: 22544389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.
    Makatini MM; Petzold K; Alves CN; Arvidsson PI; Honarparvar B; Govender P; Govender T; Kruger HG; Sayed Y; JerônimoLameira ; Maguire GE; Soliman ME
    J Enzyme Inhib Med Chem; 2013 Feb; 28(1):78-88. PubMed ID: 22339087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.
    Makatini MM; Petzold K; Sriharsha SN; Soliman ME; Honarparvar B; Arvidsson PI; Sayed Y; Govender P; Maguire GE; Kruger HG; Govender T
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2274-7. PubMed ID: 21429747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structural studies of pentacycloundecane-based HIV-1 PR inhibitors: a hybrid 2D NMR and docking/QM/MM/MD approach.
    Makatini MM; Petzold K; Sriharsha SN; Ndlovu N; Soliman ME; Honarparvar B; Parboosing R; Naidoo A; Arvidsson PI; Sayed Y; Govender P; Maguire GE; Kruger HG; Govender T
    Eur J Med Chem; 2011 Sep; 46(9):3976-85. PubMed ID: 21741133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentacycloundecane derived hydroxy acid peptides: a new class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type C-SA protease inhibitors.
    Karpoormath R; Sayed Y; Govender P; Govender T; Kruger HG; Soliman MES; Maguire GEM
    Bioorg Chem; 2012 Feb; 40(1):19-29. PubMed ID: 21982718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, screening and computational investigation of pentacycloundecane-peptoids as potent CSA-HIV PR inhibitors.
    Makatini MM; Petzold K; Arvidsson PI; Honarparvar B; Govender T; Maguire GE; Parboosing R; Sayed Y; Soliman ME; Kruger HG
    Eur J Med Chem; 2012 Nov; 57():459-67. PubMed ID: 22867528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and molecular modelling studies of novel carbapeptide analogs for inhibition of HIV-1 protease.
    Pawar SA; Jabgunde AM; Govender P; Maguire GE; Kruger HG; Parboosing R; Soliman ME; Sayed Y; Dhavale DD; Govender T
    Eur J Med Chem; 2012 Jul; 53():13-21. PubMed ID: 22542107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
    Dunn BM; Pennington MW; Frase DC; Nash K
    Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
    Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.
    Nguyen JT; Kato K; Hidaka K; Kumada HO; Kimura T; Kiso Y
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2425-9. PubMed ID: 21392990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentacycloundecane lactam vs lactone norstatine type protease HIV inhibitors: binding energy calculations and DFT study.
    Honarparvar B; Pawar SA; Alves CN; Lameira J; Maguire GE; Silva JR; Govender T; Kruger HG
    J Biomed Sci; 2015 Feb; 22(1):15. PubMed ID: 25889635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
    Yan GW; Chen Y; Li Y; Chen HF
    Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
    Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
    J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of the dimeric triad of HIV-1 aspartyl protease with inhibitors.
    Mager PP; De Clercq E; Froeyen M; Reinhardt R
    Drug Des Discov; 2003; 18(2-3):53-64. PubMed ID: 14675943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
    Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
    Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
    Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
    Seibold SA; Cukier RI
    Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations.
    Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Sanghiran V; Parasuk V; Hannongbua S
    J Mol Graph Model; 2006 Nov; 25(3):324-32. PubMed ID: 16504560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into a mutation-assisted lateral drug escape mechanism from the HIV-1 protease active site.
    Sadiq SK; Wan S; Coveney PV
    Biochemistry; 2007 Dec; 46(51):14865-77. PubMed ID: 18052195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.